ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 42315928

From bench to bedside: the evolving role of iodine in thyroid cancer management.

Condello V and 3 others. Nat Rev Endocrinol, 2026. Cited by 1 paper, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. From bench to bedside: the evolving role of iodine in thyroid cancer management. Papers, record 42315928. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42315928

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
From bench to bedside: the evolving role of iodine in thyroid cancer management.
PubMed
Journal
Nat Rev Endocrinol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-11-05
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Condello VVincenzohttps://orcid.org/0000-0003-4569-5398
2Nilsson JNJoachim N
3Zedenius JJan
4Juhlin CCC Christoferhttps://orcid.org/0000-0002-5945-9081

Source PubMed

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Thyroid NeoplasmsMajor topic
IodineMajor topic
Iodine RadioisotopesMajor topic
Humans
Translational Research, Biomedical
Animals

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References150

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134,981,7412022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?Eur Thyroid J2022https://conductscience.org/library/papers/34981741PubMed
227,494,611Comprehensive Analysis of the Transcriptional and Mutational Landscape of Follicular and Papillary Thyroid Cancers.PLoS Genet2016https://conductscience.org/library/papers/27494611PubMed
318,676,011Iodine-deficiency disorders.Lancet2008https://conductscience.org/library/papers/18676011PubMed
436,346,502Celebrating 80 years anniversary of radioiodine for use in thyroid cancer and perspectives for theranostics.Ann Nucl Med2022https://conductscience.org/library/papers/36346502PubMed
524,617,711TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer.J Clin Endocrinol Metab2014https://conductscience.org/library/papers/24617711PubMed
625,417,114Integrated genomic characterization of papillary thyroid carcinoma.Cell2014https://conductscience.org/library/papers/25417114PubMed
733,460,435Prevalence and Spectrum of DICER1 Mutations in Adult-onset Thyroid Nodules with Indeterminate Cytology.J Clin Endocrinol Metab2021https://conductscience.org/library/papers/33460435PubMed
819,773,371Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.Eur J Endocrinol2009https://conductscience.org/library/papers/19773371PubMed
922,105,174Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.J Clin Invest2011https://conductscience.org/library/papers/22105174PubMed
1016,303,836Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.J Clin Endocrinol Metab2006https://conductscience.org/library/papers/16303836PubMed

1 to 10 of 150

See all 150 references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn PapersSource
42,877,006Radioiodine-induced cGAS-STING signaling and antitumor immunity in thyroid cancer.Front Immunol2026https://conductscience.org/library/papers/42877006PubMed
42,720,506Interpretable four-class machine learning prediction of initial I-131 therapy responses in differentiated thyroid cancer.Ann Med2026https://conductscience.org/library/papers/42720506PubMed
42,708,930Predicting radioiodine therapy response in advanced and recurrent thyroid cancer.Endocr Relat Cancer2026https://conductscience.org/library/papers/42708930PubMed

Genes0

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

None in this release.

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42315928

GET https://conductscience.org/api/papers/v1/42315928/references?page=2

API referenceFor AI assistants